<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01177709</url>
  </required_header>
  <id_info>
    <org_study_id>091/C22</org_study_id>
    <nct_id>NCT01177709</nct_id>
  </id_info>
  <brief_title>Metformin for Weight Loss in Schizophrenia</brief_title>
  <official_title>Evaluation of the Efficacy of Metformin for Weight Loss and Metabolic Effects In Overweight Psychiatric Patients Treated With Antipsychotic Medication</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nathan Kline Institute for Psychiatric Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nathan Kline Institute for Psychiatric Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study hypothesis is that patients on antipsychotics medication treated with metformin will
      show loss in weight and improved measures of glucose metabolism.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who had gained more than 10 lbs of weight in the last 3 months or had BMI of 35 or
      greater were treated with metformin up to 2500 mg/day in an open label study of up to 3
      months time. Changes in weight and glucose measures were recorded.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    PI moved to different institution. Decided to concentrate on different studies.
  </why_stopped>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Weight (wt) in Pounds (Lbs)..</measure>
    <time_frame>baseline, 4 weeks, 8 weeks, 12 weeks</time_frame>
    <description>Patients weight in pounds</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glucose Levels</measure>
    <time_frame>baseline, 4 weeks, 8 weeks, 12 weeks</time_frame>
    <description>Fasting glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin Level</measure>
    <time_frame>baseline, 4 weks, 8 weeks, 12 weeks</time_frame>
    <description>fasting serum insulin uIU/ml.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>metformin 500- 2500 mg/day. Patient received variable doses of metformin starting at 500 mg/day and increasing up to maximum of 2500 mg/day over 3-4 weeks. Dose was titrated on tolerability and side effects, especially development of hypoglycemia. This explains why different patients received different maximum doses.</description>
    <arm_group_label>Metformin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients will be 18-70 years of age;

          -  Currently hospitalized or an outpatient at MPC;

          -  BMI â‰¥ 35 or excessive recent weight gain ( &gt; than 10 lb weight gain in the past 3
             months);

          -  Patients will have a diagnosis of schizophrenia or schizoaffective disorder or bipolar
             disorder.

        Exclusion Criteria:

          -  Age below 18 or over 70;

          -  Patient is currently already treated with metformin.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert C. Smith, MD PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nathan Kline Institute for Psychiatric Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Manhatan Psychiatric Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2010</study_first_submitted>
  <study_first_submitted_qc>August 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2010</study_first_posted>
  <results_first_submitted>December 15, 2016</results_first_submitted>
  <results_first_submitted_qc>December 15, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 7, 2017</results_first_posted>
  <last_update_submitted>August 2, 2017</last_update_submitted>
  <last_update_submitted_qc>August 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nathan Kline Institute for Psychiatric Research</investigator_affiliation>
    <investigator_full_name>Robert C. Smith MD PhD</investigator_full_name>
    <investigator_title>Research Psychiatrist-Principal investigator</investigator_title>
  </responsible_party>
  <keyword>schizophrenia</keyword>
  <keyword>antipsychotics</keyword>
  <keyword>obesity</keyword>
  <keyword>diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Weight Loss</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Antipsychotic Agents</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Metformin</title>
          <description>Metformin: metformin 500- 2500 mg/day.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Metformin</title>
          <description>Metformin: metformin 500- 2500 mg/day.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.5" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Weight (wt) in Pounds (Lbs)..</title>
        <description>Patients weight in pounds</description>
        <time_frame>baseline, 4 weeks, 8 weeks, 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Metformin: metformin 500- 2500 mg/day.</description>
          </group>
        </group_list>
        <measure>
          <title>Weight (wt) in Pounds (Lbs)..</title>
          <description>Patients weight in pounds</description>
          <units>weight(wt) in pounds(lbs)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline wt lbs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="250.97" spread="11.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 week wt lbs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="244.73" spread="10.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 week wt lbs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="244.15" spread="10.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 week wt lbs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="240.44" spread="9.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glucose Levels</title>
        <description>Fasting glucose</description>
        <time_frame>baseline, 4 weeks, 8 weeks, 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Metformin: metformin 500- 2500 mg/day.</description>
          </group>
        </group_list>
        <measure>
          <title>Glucose Levels</title>
          <description>Fasting glucose</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>basline glucose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111.05" spread="12.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 4 glucose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.00" spread="2.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 8 glucose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.17" spread="2.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 12 gluocse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.25" spread="3.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulin Level</title>
        <description>fasting serum insulin uIU/ml.</description>
        <time_frame>baseline, 4 weks, 8 weeks, 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Metformin: metformin 500- 2500 mg/day.</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Level</title>
          <description>fasting serum insulin uIU/ml.</description>
          <units>uIU/ml</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline insulin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.18" spread="1.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 4 insulin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.53" spread="21.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 8 insulin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.85" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 12 insulin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.29" spread="2.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Metformin</title>
          <description>Metformin: metformin 500- 2500 mg/day.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>low serum sodium,</sub_title>
                <description>patient developed low serum sodium while on additional medication chlorothiazide for kidney problems</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>penumonia</sub_title>
                <description>patient developed pneumonia after the study was completed; not related to study drug.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This is an open non-blinded study in a small number of subjects. However, it is unlikely that outcomes measures of weight, glucose, and insulin, would have been likely to be affected by non-blinding of subjects and investigators. .</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Robert C smith MD</name_or_title>
      <organization>Nathan Kline insistute for Psychiatric Research</organization>
      <phone>845-298-6531</phone>
      <email>rsmith@nki.rfmh.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

